title: ATGAM associated coagulopathy in renal transplant patients: a report of two unusual cases.
abstract: Polyclonal antibodies, used for both induction and rejection therapy in renal transplant recipients, are associated with such side effects as chills and fever. We describe two patients who developed a coagulopathy during antithymocyte globulin (ATGAM) therapy, a previously unknown complication. The laboratory tests revealed prolonged prothrombin and partial thromboplastin times and thrombocytopenia. Discontinuation of ATGAM therapy resulted in correction of these abnormalities.
authors.affiliation: Department of Internal Medicine, University of Missouri, Columbia, USA.
authors.forename: H S
authors.initials: HS
authors.lastname: Trivedi
authors.forename: S M
authors.initials: SM
authors.lastname: Lal
authors.forename: N
authors.initials: N
authors.lastname: Gupta
authors.forename: G
authors.initials: G
authors.lastname: Ross
mesh_terms: D000328:Adult; D000961:Antilymphocyte Serum / Q000009:adverse effects* / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D007676:Kidney Failure, Chronic / Q000601:surgery*; D016030:Kidney Transplantation / Q000009:adverse effects / Q000276:immunology*; D008297:Male; D010314:Partial Thromboplastin Time; D010531:Peritoneal Dialysis, Continuous Ambulatory; D011183:Postoperative Complications; D011516:Prothrombin / Q000032:analysis; D006435:Renal Dialysis; D013921:Thrombocytopenia / Q000139:chemically induced; D044465:White People
chemical_list: D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D011516:Prothrombin